Inpatient Burden of COVID-19 in Japan: A Retrospective Cohort Study

Author:

Andersen Kathleen M.ORCID,Brouillette Matthew A.,Togo Kanae,Tanabe Kosuke,Carter Benjamin T.,Kent Matthew T.,Ding Yingjie,Curcio Daniel,Welch Verna,McGrath Leah J.,Ilyas Bushra,Ito Shuhei

Abstract

ABSTRACTBackgroundChanging disease dynamics and access to COVID-19 vaccines in Japan warrant a timely description of the burden of severe disease. Here we report inpatient healthcare resource utilization of COVID-19 in Japan and contextualize results with influenza.MethodsWe selected persons hospitalized for COVID-19 (ICD-10 code U07.1) from April 1, 2020 - January 31, 2024 or influenza (ICD-10 code J09.X – J11.x) from November 1, 2017 - October 31, 2019 from Medical Data Vision, a large hospital-based database in Japan. Outcomes of interest were length of stay, intensive care unit (ICU) admission, receipt of invasive mechanical ventilation (IMV), and inpatient mortality, assessed overall, as well as stratified by age groups and calendar time.FindingsAmong 5,684 hospitalized COVID-19 cases, persons were older (median age 80 vs 64) and had a longer length of stay (median 21 vs 5 days) than the comparator 18,584 influenza cases. The proportions of patients admitted to ICU (3% vs 1%), received IMV (6% vs 3%) and died in hospital (12% vs 3%) were higher in COVID-19 patients than influenza patients. Burden was higher in adult COVID-19 patients than pediatric COVID-19 patients, although for both COVID-19 burden surpassed influenza. Inpatient burden of COVID-19 between May 2023 and January 2024 remained greater than influenza, with 5-times longer length of stay, more frequent need for ICU care (3-times higher), IMV support (2-times higher) and in-hospital deaths (4-times higher).InterpretationThese findings underscore the need for continued prevention and treatment of COVID-19 to prevent severe disease.FundingPfizer Inc.RESEARCH IN CONTEXTEvidence before this studySince COVID-19 began in March 2020, differences by region have been noted. While evidence exists regarding burden of severe COVID-19 in countries such as the United States and the United Kingdom, it was not known whether similar patterns of length of stay, admissions to the intensive care unit, receipt of invasive mechanical ventilation or in-hospital mortality were observed in Japan.Added value of this studyThese results are important, as this is the first study to describe severe COVID-19 in comparison with influenza of older adults in the inpatient setting in Japan. These data fill an evidence gap using local data. Admission to the intensive care unit, receipt of invasive mechanical ventilation and death in the hospital were more frequent in patients with COVID-19 than patients with influenza. Inpatient burden increased with age and varied over calendar time. We observed notable differences in the burden of disease and care patterns in Japan as compared to other countries.Implications of all the available evidenceContrary to the perception that the omicron variant is less severe, hospitalizations for COVID-19 have continued to accrue and cause severe disease in all ages in Japan. Once hospitalized, individuals with COVID-19 are under medical care for a substantial amount of time. Thus, preventive measures such as vaccination or early treatment to prevent severe disease are important, even in the late Omicron period.

Publisher

Cold Spring Harbor Laboratory

Reference26 articles.

1. Visualizing the data: information on COVID-19 infections [Internet]. [cited 2024 Mar 13]. Available from: https://covid19.mhlw.go.jp/en/

2. An overview of the reclassification of COVID-19 of the Infectious Diseases Control Law in Japan;Glob Health Med,2023

3. Novel Coronavirus (COVID-19) [Internet]. [cited 2024 Mar 13]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000164708_00079.html

4. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE) | The BMJ [Internet]. [cited 2024 Feb 7]. Available from: https://www.bmj.com/content/363/bmj.k3532.full

5. Inventory of real-world data sources in Japan: Annual survey conducted by the Japanese Society for Pharmacoepidemiology Task Force;Pharmacoepidemiol Drug Saf,2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3